CompletedPhase 2

Efficacy of Eflornithine Hydrochloride Cream in the Treatment of Melasma: A Randomized, Double-blinded, Split-face Controlled Study

Singapore20 participantsStarted 2023-06-06

Plain-language summary

The goal of this clinical trial is to learn if Eflornithine hydrochloride cream works to treat melasma in adults, in comparison to Hydroquinone cream. It will also learn about the safety of Eflornithine hydrochloride cream. The main questions it aims to answer are: * Does Eflornithine hydrochloride improve melasma assessment scores over a 3-month duration compared to Hydroquinone cream? * What side effects might patients get while using Eflornithine hydrochloride cream? Participants will: * Apply both Eflornithine hydrochloride and Hydroquinone creams on separate halves of their faces every day for 3 months. * Visit the clinic once at the 2-month mark and once at the 3-month mark for checkups and tests.

Who can participate

Age range25 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical diagnosis of melasma * Fitzpatrick Type III or IV * Able to provide informed consent Exclusion Criteria: * Pregnant or lactating patients * Patients with difficulty adhering to regular topical treatments * Patients with known contact allergies to any of the ingredients in the topical medications used in the study

What they're measuring

Modified Melasma Area and Severity Index (mMASI)

Timeframe: At 8 weeks and 12 weeks

Mexameter melanin score

Timeframe: At 8 and 12 weeks

Trial details

NCT IDNCT06957834

SponsorNational Skin Centre

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2024-07-11

View on ClinicalTrials.gov More Melasma trials